Moreover, the FXR novel antagonist glycine-β-muricholic acid, which is retained in the gut, has the potential to enhance glycolipid metabolism in obesity and NAFLD [199]. The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatotic liver disease.